Related Experiment Video

Updated: Jun 13, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Role of mitochondrial amyloid-beta in Alzheimer's disease

John Xi Chen1, Shirley Shidu Yan

  • 1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Journal of Alzheimer'S Disease : JAD
|May 14, 2010
PubMed

Insights

Alzheimer's disease (AD) involves mitochondrial dysfunction, with amyloid-beta (Abeta) accumulating in mitochondria. This Abeta accumulation drives neurotoxicity and offers therapeutic targets for AD.

Area of Science:

  • Neuroscience
  • Mitochondrial Biology
  • Alzheimer's Disease Research

Background:

  • Mitochondrial dysfunction is an early hallmark of Alzheimer's disease (AD).
  • Key mitochondrial abnormalities include impaired energy metabolism, oxidative stress, and altered permeability.
  • The precise mechanisms driving mitochondrial dysfunction in AD are not fully understood.

Purpose of the Study:

  • To review recent evidence on amyloid-beta (Abeta) accumulation within mitochondria in AD.
  • To explore how Abeta accesses mitochondria and its subsequent impact on mitochondrial function.
  • To investigate the mechanisms of Abeta-induced mitochondrial and neuronal toxicity in AD pathogenesis.

Main Methods:

  • Review of existing literature and studies on Alzheimer's disease brain and AD mouse models.
  • Analysis of mechanisms for Abeta entry into mitochondria.
  • Examination of Abeta's interaction with mitochondrial binding partners like cyclophilin D and ABAD.

Main Results:

  • Substantial evidence indicates progressive accumulation of mitochondrial Abeta in AD.
  • Mitochondrial Abeta correlates with impaired mitochondrial function and increased oxidative stress.
  • Abeta interaction with cyclophilin D and ABAD exacerbates mitochondrial and neuronal dysfunction.

Conclusions:

  • Mitochondrial Abeta accumulation is a significant contributor to neurotoxicity in Alzheimer's disease.
  • Understanding these mechanisms provides critical insights for developing novel therapeutic strategies for AD.
  • Targeting mitochondrial Abeta and its interactions may offer a promising therapeutic avenue for AD.

More Related Videos

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models08:48

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Published on: June 30, 2023

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...